PR Newswire

Brand Post September 8, 2024

Eisai to Present E7386, co-created by PRISM BioLab and Eisai, at the ESMO (European Society for Medical Oncology) Annual Meeting

Abstract Released for E7386, Created Through Collaborative Research Between Eisai and PRISM TOKYO, Sept. 8, 2024 /PRNewswire/ — PRISM BioLab, Co.…

Brand Post September 8, 2024

Toshiba Unveils the High-End Masterstroke Series at IFA 2024, Showcasing a New Era of Masterpiece Appliances

BERLIN, Sept. 8, 2024 /PRNewswire/ — Toshiba, a brand renowned for its over a century of excellence in craftsmanship and…

Brand Post September 8, 2024

Saudi Arabia’s landmark Global AI Summit to address harnessing AI for the good of humanity

RIYADH, Saudi Arabia, Sept. 8, 2024 /PRNewswire/ — Ahead of the Global AI Summit (GAIN) this week, H.E. Dr. Abdullah bin…

Brand Post September 8, 2024

ALIMENTATION COUCHE-TARD COMMENTS ON SEVEN & I HOLDINGS’ RESPONSE NOT TO ENGAGE IN FRIENDLY DISCUSSIONS REGARDING A VALUE CREATING COMBINATION

LAVAL, QC, Sept. 8, 2024 /PRNewswire/ – Alimentation Couche-Tard Inc. (“Couche-Tard” or the “Corporation”) (TSX: ATD), a global leader in…

Brand Post September 8, 2024

Resecurity Partners with Mannai Trading Corporation to Bolster Cybersecurity in Qatar

LOS ANGELES, Sept. 8, 2024 /PRNewswire/ — Resecurity, a global leader in cybersecurity solutions protecting Fortune 100 corporations and government agencies…

Brand Post September 8, 2024

ICEYE to deliver SAR satellites and data to Greece’s National Satellite Space Project in collaboration with the European Space Agency

SAR satellites and data enable Greece to monitor their areas of interest and improve their natural catastrophe detection and maritime…

Brand Post September 8, 2024

Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024

HONG KONG, Sept. 8, 2024 /PRNewswire/ — Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed…

Brand Post September 8, 2024

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer

New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT® plus LAZCLUZE™ regimen compared to osimertinib monotherapy…

Brand Post September 8, 2024

PanCan Nodule Management Protocol More Effective Than LungRADSv1.1 Method

New data presented today reveals that the PanCan nodule management protocol demonstrates superior performance in triaging lung cancer screening participants…

Brand Post September 8, 2024

Perioperative Nivolumab May Provide Meaningful Improvement in Event-Free Survival Compared to only Neoadjuvant Nivolumab Plus Chemotherapy for Resectable NSCLC

New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with resectable…

Brand Post September 8, 2024

Ivonescimab Outperforms Pembrolizumab in Phase 3 Study for First-Line Treatment of PD-L1-Positive Advanced NSCLC In HARMONi-2 Study

Data from a Phase 3 study revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival…

Brand Post September 8, 2024

NeoCOAST-2 Data Shows Combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC — Data Builds on AEGEAN Study Research

Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete…

Brand Post September 8, 2024

Eisai to Present E7386, co-created by PRISM BioLab and Eisai, at the ESMO (European Society for Medical Oncology) Annual Meeting

Toshiba Unveils the High-End Masterstroke Series at IFA 2024, Showcasing a New Era of Masterpiece Appliances

Saudi Arabia’s landmark Global AI Summit to address harnessing AI for the good of humanity

ALIMENTATION COUCHE-TARD COMMENTS ON SEVEN & I HOLDINGS’ RESPONSE NOT TO ENGAGE IN FRIENDLY DISCUSSIONS REGARDING A VALUE CREATING COMBINATION

Resecurity Partners with Mannai Trading Corporation to Bolster Cybersecurity in Qatar

ICEYE to deliver SAR satellites and data to Greece’s National Satellite Space Project in collaboration with the European Space Agency

Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer

PanCan Nodule Management Protocol More Effective Than LungRADSv1.1 Method

Perioperative Nivolumab May Provide Meaningful Improvement in Event-Free Survival Compared to only Neoadjuvant Nivolumab Plus Chemotherapy for Resectable NSCLC

Ivonescimab Outperforms Pembrolizumab in Phase 3 Study for First-Line Treatment of PD-L1-Positive Advanced NSCLC In HARMONi-2 Study

NeoCOAST-2 Data Shows Combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC — Data Builds on AEGEAN Study Research

AdvisorVault’s 17a-4 Managed 365 Service: Finally, Guaranteed FINRA Compliance On The Microsoft Cloud

Akeso’s Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled at WCLC 2024

Program-Ace and VirtualSpeech Join Efforts to Drive Innovation in VR Soft Skills Development for Organizations